alanine has been researched along with Local Neoplasm Recurrence in 8 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study is to evaluate the relationship between the aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) ratio and local disease control in patients with head and neck squamous cell carcinomas (HNSCC) treated with radiotherapy/chemoradiotherapy." | 8.02 | The aspartate aminotransaminase/alanine aminotransaminase (De Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients. ( Avilés-Jurado, FX; León, X; Pardo, L; Quer, M; Sansa, A; Terra, X; Valero, C; Venegas, MDP, 2021) |
| "Rabacfosadine (RAB), a novel antineoplastic agent conditionally licensed for the treatment of lymphoma in dogs, is efficacious in both naïve and previously treated dogs." | 7.96 | Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs. ( Bergman, PJ; Cawley, JR; Clifford, CA; Meleo, K; Post, GS; Thamm, DH; Vail, DM; Vickery, KR; Wright, ZM, 2020) |
| "Brivanib is an oral, tyrosine kinase inhibitor against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR)." | 6.84 | A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. ( Aghajanian, C; Bonebrake, AJ; Chafe, W; Chan, JK; Deng, W; Gaillard, S; Hicks, M; Higgins, RV; Monk, BJ; Ramirez, PT; Tewari, KS, 2017) |
| "The aim of this study is to evaluate the relationship between the aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) ratio and local disease control in patients with head and neck squamous cell carcinomas (HNSCC) treated with radiotherapy/chemoradiotherapy." | 4.02 | The aspartate aminotransaminase/alanine aminotransaminase (De Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients. ( Avilés-Jurado, FX; León, X; Pardo, L; Quer, M; Sansa, A; Terra, X; Valero, C; Venegas, MDP, 2021) |
| "Rabacfosadine (RAB), a novel antineoplastic agent conditionally licensed for the treatment of lymphoma in dogs, is efficacious in both naïve and previously treated dogs." | 3.96 | Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs. ( Bergman, PJ; Cawley, JR; Clifford, CA; Meleo, K; Post, GS; Thamm, DH; Vail, DM; Vickery, KR; Wright, ZM, 2020) |
| "Brivanib is an oral, tyrosine kinase inhibitor against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR)." | 2.84 | A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. ( Aghajanian, C; Bonebrake, AJ; Chafe, W; Chan, JK; Deng, W; Gaillard, S; Hicks, M; Higgins, RV; Monk, BJ; Ramirez, PT; Tewari, KS, 2017) |
| " Assessments included adverse events, PK, tumour response, 2[18F]fluoro-2-deoxyglucose positron-emitting tomography and K-Ras mutation analyses." | 2.76 | Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. ( Buter, J; Chemidlin, J; El-Khoueiry, A; Feltquate, D; Ford, S; Galbraith, S; Garrett, CR; Hayes, W; Kollia, G; LoRusso, P; Major, P; Marshall, J; Mokliatchouk, O; Nuyten, DS; Rocha-Lima, CM; Siu, LL; Syed, S; Velasquez, L, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Cawley, JR | 1 |
| Wright, ZM | 1 |
| Meleo, K | 1 |
| Post, GS | 1 |
| Clifford, CA | 1 |
| Vickery, KR | 1 |
| Vail, DM | 1 |
| Bergman, PJ | 1 |
| Thamm, DH | 1 |
| Sansa, A | 1 |
| Venegas, MDP | 1 |
| Valero, C | 1 |
| Pardo, L | 1 |
| Avilés-Jurado, FX | 1 |
| Terra, X | 1 |
| Quer, M | 1 |
| León, X | 1 |
| Gadzińska, J | 1 |
| Kuchar, E | 1 |
| Matysiak, M | 1 |
| Wanke-Rytt, M | 1 |
| Kloc, M | 1 |
| Kubiak, JZ | 1 |
| Chan, JK | 1 |
| Deng, W | 1 |
| Higgins, RV | 1 |
| Tewari, KS | 1 |
| Bonebrake, AJ | 1 |
| Hicks, M | 1 |
| Gaillard, S | 1 |
| Ramirez, PT | 1 |
| Chafe, W | 1 |
| Monk, BJ | 1 |
| Aghajanian, C | 1 |
| Powell, MA | 1 |
| Sill, MW | 1 |
| Goodfellow, PJ | 1 |
| Benbrook, DM | 1 |
| Lankes, HA | 1 |
| Leslie, KK | 1 |
| Jeske, Y | 1 |
| Mannel, RS | 1 |
| Spillman, MA | 1 |
| Lee, PS | 1 |
| Hoffman, JS | 1 |
| McMeekin, DS | 1 |
| Pollock, PM | 1 |
| Garrett, CR | 1 |
| Siu, LL | 1 |
| El-Khoueiry, A | 1 |
| Buter, J | 1 |
| Rocha-Lima, CM | 1 |
| Marshall, J | 1 |
| LoRusso, P | 1 |
| Major, P | 1 |
| Chemidlin, J | 1 |
| Mokliatchouk, O | 1 |
| Velasquez, L | 1 |
| Hayes, W | 1 |
| Feltquate, D | 1 |
| Syed, S | 1 |
| Ford, S | 1 |
| Kollia, G | 1 |
| Galbraith, S | 1 |
| Nuyten, DS | 1 |
| Masaki, T | 1 |
| Sugiyama, M | 1 |
| Matsuoka, H | 1 |
| Abe, N | 1 |
| Izumisato, Y | 1 |
| Goto, A | 1 |
| Sakamoto, A | 1 |
| Atomi, Y | 1 |
| Elson, PJ | 1 |
| Kvols, LK | 1 |
| Vogl, SE | 1 |
| Glover, DJ | 1 |
| Hahn, RG | 1 |
| Trump, DL | 1 |
| Carbone, PP | 1 |
| Earle, JD | 1 |
| Davis, TE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)[NCT01267253] | Phase 2 | 31 participants (Actual) | Interventional | 2011-04-04 | Completed | ||
| An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma[NCT03694262] | Phase 2 | 30 participants (Actual) | Interventional | 2019-07-19 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Proportion of participants with objective tumor response. Objective tumor response is defined as complete or partial tumor response assessed by RECIST 1.1 (NCT01267253)
Timeframe: Every other cycle for first 6 months; then every 3 months thereafter until disease progression confirmed; and at any other time if clinically indicated based on symptoms or physical signs suggestive of progressive disease.
| Intervention | proportion (Number) |
|---|---|
| Brivanib | 0.071 |
Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.. (NCT01267253)
Timeframe: From study entry to time of death or the date of last contact, up to 5 years of follow-up.
| Intervention | Months (Median) |
|---|---|
| Brivanib | 7.9 |
Proportion of participants who survive progression-free for at least 6 months without non-protocol therapy from study entry. Progression is assessed by RECIST 1.1. (NCT01267253)
Timeframe: Every other cycle for first 6 months; then every 3 months therafter until disease progression confirmed; and at any other time if cliniclly indicated based on symptoms or physical signs suggestive of progressive disease
| Intervention | proportion (Number) |
|---|---|
| Brivanib | 0.179 |
Progression-free survival is the period of time from study entry to time of disease progression, death or date of last contact, whichever occurs first. Progression is assessed by RECIST 1.1 (NCT01267253)
Timeframe: From study entry to time of progression or death, whichever occurs first, up to 5 years of follow-up
| Intervention | Months (Median) |
|---|---|
| Brivanib | 3.2 |
Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v.4.0 (NCT01267253)
Timeframe: During treatment period and up to 30 days after stopping the study treatment.
| Intervention | Participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukopenia | Thrombocytopenia | Neutropenia | Anemia | Other Investigations | Cardiac Disorders | Gastrointestinal Disorders | General disorders & administration site conditions | Hepatobiliary Disorders | Infections and infestations | Metabolism and nutrition disorders | Musculoskeletal & connective tissue disorders | Neoplasms benign, malignant & unspecified | Nervous system disorders | Renal and urinary disorders | Vascular Disorders | |
| Brivanib | 0 | 0 | 0 | 4 | 4 | 1 | 7 | 2 | 1 | 4 | 5 | 3 | 2 | 3 | 2 | 5 |
3 trials available for alanine and Local Neoplasm Recurrence
5 other studies available for alanine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs.
Topics: Alanine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginas | 2020 |
The aspartate aminotransaminase/alanine aminotransaminase (De Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients.
Topics: Alanine; Alanine Transaminase; Aspartate Aminotransferases; Aspartic Acid; Biomarkers, Tumor; Carcin | 2021 |
A 10-Year-old Girl With Late Acute Lymphoblastic Leukemia Recurrence Diagnosed With COVID-19 and Treated With Remdesivir.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Child; COVID-19; COVID-19 Drug Treatment; Female | 2022 |
Clinical utility of grading criteria for submucosal invasion in the prognosis of T1 colorectal carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Alanine; alpha Catenin; Cadherins; Colorectal Neoplasms; Cytoskeleta | 2003 |
Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma.
Topics: Adult; Aged; Alanine; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Dr | 1988 |